NY Times on the Dark Side of Buprenorphine
A very long article in the New York Times this morning examines both the benefits and considerable adverse consequences of using buprenorphine to treat opiate addiction. The piece points out that although many people have not heard of buprenorphine, its $1.55 billion in U.S. sales last year topped even the figures for Viagra. And with the Affordable Care Act set to expand treatment for drug addiction, problems with buprenorphine profiteering, diversion and overdose seem likely to get much worse.
The availability of a sublingual dissolvable strip from of the drug has led to inventive ways of hiding and smuggling doses. A p...
Source: The Poison Review - November 17, 2013 Category: Toxicology Authors: Leon Tags: Medical abuse buprenorphine diversion new york times overdose suboxone subutex zubsolv Source Type: news
The Double-Edged Drug: Addiction Treatment With a Dark Side
High hopes for buprenorphine, an effective treatment for opioid addiction, have been tempered by a messy reality: health complications and deaths, unscrupulous doctors and a reputation as a street drug. (Source: NYT Health)
Source: NYT Health - November 16, 2013 Category: Consumer Health News Authors: By DEBORAH SONTAG Tags: CVS Caremark Corporation CVS NYSE Suboxone (Drug) LinkedIn Corporation LNKD NYSE Walgreen Company WAG NYSE Addiction (Psychology) Source Type: news
The Double-Edged Drug: In Demand in Clinics and on the Street, ‘Bupe’ Can Be Savior or Menace
High hopes for buprenorphine, an effective treatment for opioid addiction, have been tempered by a messy reality: health complications and deaths, unscrupulous doctors and a reputation as a street drug. (Source: NYT Health)
Source: NYT Health - November 16, 2013 Category: Consumer Health News Authors: By DEBORAH SONTAG Tags: CVS Caremark Corporation CVS NYSE Suboxone (Drug) LinkedIn Corporation LNKD NYSE Walgreen Company WAG NYSE Addiction (Psychology) Source Type: news
Mind Meets Body: Developing a Psychology Internship in a Family Medicine Residency Program (Raymond Hornyak PhD)
Mind Meets Body:
Creating a Primary Care Psychology
Internship in a Family Medicine
Residency Program
Introduction:
Multiple studies have identified the benefits of providing behavioral health services to primary care patients. Decreased length of stay, fewer hospitalizations and emergency room visits, less frequent office visits, fewer prescriptions, and improvement in health outcomes have been associated with the availability of a behavioral health professional as part of an integrative primary care network. Family physicians have found behavioral health colleagues a valuable resource in which to refer their "...
Source: Family Medicine Digital Resources Library (FMDRL) Recently Uploaded - November 14, 2013 Category: Primary Care Source Type: news
Advertising Drugs to Addicts
A glut of information about prescription drugs makes it easy for addicts to get their fix from doctors. But worst of all, celebrities are now the pushers.read more (Source: Psychology Today Addiction Center)
Source: Psychology Today Addiction Center - October 22, 2013 Category: Addiction Authors: Anna B. David Tags: Addiction Media adderall ADHD big pharma Heath Ledger narcotic PPO Prescription prescription drugs suboxone vicodin Source Type: news
Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning - Häkkinen M, Heikman P, Ojanperä I.
Buprenorphine (BPN) medication for opioid maintenance treatment in Finland consists predominantly of buprenorphine-naloxone (BNX). Both BPN and BNX are associated with diversion, abuse and non-medically supervised use worldwide. Our purpose was to estimate... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - October 1, 2013 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news
Zubsolv (Buprenorphine and Naloxone) - Maintenance Treatment for Opioid Dependence
Zubsolv (buprenorphine and naloxone) is a sublingual tablet indicated as maintenance treatment for people suffering from opioid dependence. (Source: Drug Development Technology)
Source: Drug Development Technology - July 29, 2013 Category: Pharmaceuticals Source Type: news
Zubsolv (Buprenorphine and Naloxone Sublingual Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 18, 2013 Category: Drugs & Pharmacology Source Type: news
FDA OKs New Formula for Addiction Drug
(MedPage Today) -- The FDA has approved a new sublingual tablet formulation of the opioid addiction drug buprenorphine-naloxone (Zubsolv), drugmaker Orexo U.S. announced. (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - July 8, 2013 Category: Psychiatry Source Type: news
Orexo starts patient dosing in Phase III study of opioid dependence drug
Sweden-based Orexo has commenced patient dosing in a Phase III study to evaluate Zubsolv, a sublingual formulation of buprenorphine and naloxone. (Source: Drug Development Technology)
Source: Drug Development Technology - June 17, 2013 Category: Pharmaceuticals Source Type: news
Not Otherwise Specified: Anxiety & the Work of Dr. Robert Hudak
Southwest Pennsylvania National Alliance on Mental Illness (NAMI) held its annual conference at the beginning of April, and one of their afternoon breakout workshop presenters was Dr. Robert Hudak, assistant professor of psychiatry at Western Psychiatric Institute & Clinic, University of Pittsburgh. “Pathways to Hope: Shaping a Positive Future in Uncertain Times” was the conference topic; Dr. Hudak’s contribution was “Coping with Anxiety and Panic Attacks.”
I communicated with Dr. Hudak recently, to clarify some questions, get his take on some extrapolations of anxiety and even to inquire about an interesti...
Source: Psych Central - May 13, 2013 Category: Psychiatry Authors: Lisa A. Miles Tags: Addictions Alcoholism Anti-anxiety Cognitive-Behavioral Disorders Dual Diagnosis General Medications Obsessive-Compulsive Disorder Psychology Psychotherapy Substance Abuse Treatment Anxiety And Panic Attacks Breakout Workshops Source Type: news
Novel Opioid Dependence Pill Gets Patients' Thumbs-UpNovel Opioid Dependence Pill Gets Patients' Thumbs-Up
Compared with buprenorphine-naloxone sublingual film to treat opioid dependence, a sublingual menthol-flavored tablet has a preferred taste and comparable dissolve time. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 1, 2013 Category: Consumer Health News Tags: Psychiatry News Source Type: news
Jennifer Serrentino, M.D. Recently Launches a Blog Post Discussing the...
Well known local psychiatrist, Jennifer Serrentino, M.D., recently discusses the Suboxone controversy on her blog.(PRWeb April 19, 2013)Read the full story at http://www.prweb.com/releases/Local-Port-Jefferson/Psychiatrist-Jennifer-Ser/prweb10636625.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 23, 2013 Category: Pharmaceuticals Source Type: news
PMO Launches New Suboxone ® Medication AssistedTreatment Plus...
PMO Care announces implementation of Suboxone and Vivitrol Medication Assisted Treatment in conjunction with on-site counseling for...(PRWeb February 27, 2013)Read the full story at http://www.prweb.com/releases/2013/2/prweb10470251.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 27, 2013 Category: Pharmaceuticals Source Type: news
FDA Permits Production Of Generic Heroin Drug Against Bid Of Reckitt
Two generic forms of Reckitt Benckiser's heroin addiction medication have been approved by U.S. regulators, rejecting the company's bid to prevent rival products based on their belief that stricter regulations were needed on packages to better protect children. Reckitt Benckiser, a British consumer health products company, makes a good portion of its earnings from Suboxone, a medication that has buprenorphine and helps people who are addicted to opiates deal with withdrawal symptoms when they quit... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 26, 2013 Category: Consumer Health News Tags: Regulatory Affairs / Drug Approvals Source Type: news
